Maravai LifeSciences Holdings, Inc.
General ticker "MRVI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $853.4M (TTM average)
Maravai LifeSciences Holdings, Inc. follows the US Stock Market performance with the rate: 35.9%.
Estimated limits based on current volatility of 3.2%: low 3.79$, high 4.04$
Factors to consider:
- Total employees count: 570 (0.0%) as of 2024
- North America accounted for 48.8% of revenue in the fiscal year ended 2023-12-31
- Top business risk factors: Dependency on cleancap sales, Customer spending and demand, Labor/talent shortage/retention, Product quality issues, Government policy changes
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.42$, 7.71$]
- 2025-12-31 to 2026-12-31 estimated range: [3.63$, 7.89$]
Financial Metrics affecting the MRVI estimates:
- Positive: with PPE of -30.2 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Industry operating cash flow (median)
- Positive: -4.41 < Investing cash flow per share per price, % of -3.24
- Positive: 0.04 < Operating cash flow per share per price, % of 1.00
- Positive: 19.35 < Shareholder equity ratio, % of 32.26 <= 42.53
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term MRVI quotes
Long-term MRVI plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $883.00MM | $288.94MM | $259.19MM |
| Operating Expenses | $308.79MM | $320.59MM | $494.80MM |
| Operating Income | $574.22MM | $-31.65MM | $-235.62MM |
| Non-Operating Income | $-22.74MM | $649.38MM | $-25.86MM |
| Interest Expense | $20.41MM | $45.89MM | $47.70MM |
| R&D Expense | $18.37MM | $17.28MM | $19.22MM |
| Income(Loss) | $551.47MM | $617.74MM | $-261.48MM |
| Taxes | $60.81MM | $756.11MM | $-1.86MM |
| Profit(Loss)* | $220.21MM | $-119.03MM | $-144.85MM |
| Stockholders Equity | $545.22MM | $416.75MM | $325.29MM |
| Inventory | $43.15MM | $51.40MM | $50.08MM |
| Assets | $2,282.32MM | $1,487.45MM | $1,008.24MM |
| Operating Cash Flow | $535.98MM | $126.22MM | $7.46MM |
| Capital expenditure | $17.09MM | $65.55MM | $29.66MM |
| Investing Cash Flow | $-267.61MM | $-122.31MM | $-24.32MM |
| Financing Cash Flow | $-187.50MM | $-61.09MM | $-235.71MM |
| Earnings Per Share** | $1.67 | $-0.90 | $-1.05 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.